Patient Name : Mr.

CHANDAN TANTI Collected : 31/Aug/2023 10:13AM

Age/Gender : 23 Y 0 M 0 D /M Received : 31/Aug/2023 05:20PM
UHID/MR No : DSNG.0000003266 Reported : 31/Aug/2023 05:29PM
Visit ID : DSNGOPV4501 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC SAGARBHANGA
IP/OP NO : Patient location : RANIGANJ,RANIGANJ

DEPARTMENT OF HAEMATOLOGY
Test Name Result Unit Bio. Ref. Range Method

COMPLETE BLOOD COUNT (CBC) , WHOLE BLOOD EDTA

HAEMOGLOBIN 14.2 g/dL 13-17 CYANIDE FREE
COLOUROMETER
PCV 43.70 % 40-50 PULSE HEIGHT AVERAGE
RBC COUNT 5.03 Million/cu.mm 4.5-5.5 Electrical Impedence
MCV 86.9 fL 83-101 Calculated
MCH 28.2 pg 27-32 Calculated
MCHC 32.4 g/dL 31.5-34.5 Calculated
R.D.W 14.4 % 11.6-14 Calculated
TOTAL LEUCOCYTE COUNT (TLC) 8,900 cells/cu.mm 4000-10000 Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DLC)
NEUTROPHILS 49 % 40-80 Electrical Impedance
LYMPHOCYTES 46 % 20-40 Electrical Impedance
EOSINOPHILS 03 % 1-6 Electrical Impedance
MONOCYTES 02 % 2-10 Electrical Impedance
BASOPHILS 00 % <1-2 Electrical Impedance
CORRECTED TLC 8,900 Cells/cu.mm Calculated
ABSOLUTE LEUCOCYTE COUNT
NEUTROPHILS 4361 Cells/cu.mm 2000-7000 Electrical Impedance
LYMPHOCYTES 4094 Cells/cu.mm 1000-3000 Electrical Impedance
EOSINOPHILS 267 Cells/cu.mm 20-500 Electrical Impedance
MONOCYTES 178 Cells/cu.mm 200-1000 Electrical Impedance
PLATELET COUNT 155000 cells/cu.mm 150000-410000 IMPEDENCE/MICROSCOPY

Page 1 of 10

SIN No:HA05578497
This test is performed by Apollo Diagnostics Lab in collaboration with Avishkar Diagnostics
Patient Name : Mr.CHANDAN TANTI Collected : 31/Aug/2023 10:13AM
Age/Gender : 23 Y 0 M 0 D /M Received : 31/Aug/2023 05:20PM
UHID/MR No : DSNG.0000003266 Reported : 31/Aug/2023 05:42PM
Visit ID : DSNGOPV4501 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC SAGARBHANGA
IP/OP NO : Patient location : RANIGANJ,RANIGANJ

DEPARTMENT OF HAEMATOLOGY
Test Name Result Unit Bio. Ref. Range Method

BLOOD GROUP ABO AND RH FACTOR , WHOLE BLOOD EDTA

BLOOD GROUP TYPE O Forward & Reverse
Grouping with
Slide/Tube Aggluti
Rh TYPE POSITIVE Forward & Reverse
Grouping with
Slide/Tube
Agglutination

THIS IS A SCREENING TEST, PLEASE CONFIRM BY CONFIRMATORY METHOD.

Page 2 of 10

SIN No:HA05578497
This test is performed by Apollo Diagnostics Lab in collaboration with Avishkar Diagnostics
Patient Name : Mr.CHANDAN TANTI Collected : 01/Sep/2023 03:41PM
Age/Gender : 23 Y 0 M 0 D /M Received : 01/Sep/2023 07:33PM
UHID/MR No : DSNG.0000003266 Reported : 01/Sep/2023 08:21PM
Visit ID : DSNGOPV4501 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC SAGARBHANGA
IP/OP NO : Patient location : RANIGANJ,RANIGANJ

DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Range Method

GLUCOSE, FASTING , NAF PLASMA 80 mg/dL 70-100 HEXOKINASE

Result is rechecked. Kindly correlate clinically

Comment:
As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL Interpretation

70-100 mg/dL Normal
100-125 mg/dL Prediabetes
≥126 mg/dL Diabetes
<70 mg/dL Hypoglycemia

Note:
1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of
> or = 200 mg/dL on at least 2 occasions.
2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2 70 mg/dL 70-140 GOD - POD

HOURS , SODIUM FLUORIDE PLASMA (2
HR)

Result is rechecked twice from received sample. Kindly correlate clinically

Comment:
It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each
other.
Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive
hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin
preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Ref: Marks medical biochemistry and clinical approach

Page 3 of 10

SIN No:BI15853710,BI15873670
This test is performed by Apollo Diagnostics Lab in collaboration with Avishkar Diagnostics
Patient Name : Mr.CHANDAN TANTI Collected : 31/Aug/2023 10:13AM
Age/Gender : 23 Y 0 M 0 D /M Received : 31/Aug/2023 05:20PM
UHID/MR No : DSNG.0000003266 Reported : 31/Aug/2023 09:37PM
Visit ID : DSNGOPV4501 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC SAGARBHANGA
IP/OP NO : Patient location : RANIGANJ,RANIGANJ

DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Range Method

HBA1C, GLYCATED HEMOGLOBIN , 5 % HPLC

WHOLE BLOOD EDTA
ESTIMATED AVERAGE GLUCOSE (eAG) , 97 mg/dL Calculated
WHOLE BLOOD EDTA

Comment:
Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP HBA1C %

NON DIABETIC <5.7
PREDIABETES 5.7 – 6.4
DIABETES ≥ 6.5
DIABETICS
EXCELLENT CONTROL 6–7
FAIR TO GOOD CONTROL 7–8
UNSATISFACTORY CONTROL 8 – 10
POOR CONTROL >10

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by
American Diabetes Association guidelines 2023.
2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic
Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or
decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect
erythrocyte survival are present.
5. In cases of Interference of Hemoglobin variants in HbA1C alternative methods (Fructosamine) estimation is recommended
for Glycemic Control
A: HbF >25%
B: Homozygous Hemoglobinopathy.
(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 4 of 10

SIN No:BI15853713
This test is performed by Apollo Diagnostics Lab in collaboration with Avishkar Diagnostics
Patient Name : Mr.CHANDAN TANTI Collected : 31/Aug/2023 10:13AM
Age/Gender : 23 Y 0 M 0 D /M Received : 31/Aug/2023 05:25PM
UHID/MR No : DSNG.0000003266 Reported : 31/Aug/2023 05:54PM
Visit ID : DSNGOPV4501 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC SAGARBHANGA
IP/OP NO : Patient location : RANIGANJ,RANIGANJ

DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Range Method

LIPID PROFILE , SERUM

TOTAL CHOLESTEROL 167 mg/dL <200 CHO-POD
TRIGLYCERIDES 177 mg/dL <150 GPO-POD
HDL CHOLESTEROL 48 mg/dL 40-60 Enzymatic
Immunoinhibition
NON-HDL CHOLESTEROL 119 mg/dL <130 Calculated
LDL CHOLESTEROL 83.6 mg/dL <100 Calculated
VLDL CHOLESTEROL 35.4 mg/dL <30 Calculated
CHOL / HDL RATIO 3.48 0-4.97 Calculated

Comment:
Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

Desirable Borderline High High Very High

TOTAL CHOLESTEROL < 200 200 - 239 ≥ 240
TRIGLYCERIDES <150 150 - 199 200 - 499 ≥ 500
Optimal < 100
LDL 130 - 159 160 - 189 ≥ 190
Near Optimal 100-129
HDL ≥ 60
Optimal <130;
NON-HDL CHOLESTEROL 160-189 190-219 >220
Above Optimal 130-159

1.Measurements in the same patient on different days can show physiological and analytical variations.
2.NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
3.Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine
eligibility of drug therapy.
4.Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse
cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
5.As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children
above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total
cholesterol is recommended.
6.VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when
Triglycerides are below 350 mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 5 of 10

SIN No:BI15853712
This test is performed by Apollo Diagnostics Lab in collaboration with Avishkar Diagnostics
Patient Name : Mr.CHANDAN TANTI Collected : 31/Aug/2023 10:13AM
Age/Gender : 23 Y 0 M 0 D /M Received : 31/Aug/2023 05:25PM
UHID/MR No : DSNG.0000003266 Reported : 31/Aug/2023 05:54PM
Visit ID : DSNGOPV4501 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC SAGARBHANGA
IP/OP NO : Patient location : RANIGANJ,RANIGANJ

DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Range Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM

CREATININE 0.67 mg/dL 0.72 – 1.18 ENZYMATIC METHOD
UREA 22.20 mg/dL 17-43 GLDH, Kinetic Assay
BLOOD UREA NITROGEN 10.4 mg/dL 8.0 - 23.0 Calculated
URIC ACID 6.27 mg/dL 3.5–7.2 Uricase PAP
CALCIUM 10.11 mg/dL 8.8-10.6 Arsenazo III
PHOSPHORUS, INORGANIC 4.66 mg/dL 2.5-4.5 Phosphomolybdate
Complex
SODIUM 138.5 mmol/L 136–146 ISE (Indirect)
POTASSIUM 3.5 mmol/L 3.5–5.1 ISE (Indirect)
CHLORIDE 99.8 mmol/L 101–109 ISE (Indirect)

Page 6 of 10

SIN No:BI15853712
This test is performed by Apollo Diagnostics Lab in collaboration with Avishkar Diagnostics
Patient Name : Mr.CHANDAN TANTI Collected : 31/Aug/2023 10:13AM
Age/Gender : 23 Y 0 M 0 D /M Received : 31/Aug/2023 05:24PM
UHID/MR No : DSNG.0000003266 Reported : 31/Aug/2023 06:07PM
Visit ID : DSNGOPV4501 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC SAGARBHANGA
IP/OP NO : Patient location : RANIGANJ,RANIGANJ

DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Range Method

THYROID STIMULATING HORMONE 1.886 µIU/mL 0.34-5.60 CLIA

(TSH) , SERUM

Comment:

1.TSH is a labile hormone & is secreted in a pulsatile manner throughout the day and is subject to several endogenous &
exogenous influences. It has to be noted that oscillation in TSH occurs throughout the day leading to with-in day variations of TSH
measurements.
2.Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication &
circulating antibodies.
3.TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of
normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively. Nocturnal increase in TSH may be
lost in critical illness or after surgery. In the first trimester of pregnancy, TSH concentrations decline as hCG stimulates maternal
thyroid gland to produce thyroid hormone.
4.Transient increase in TSH levels or abnormal TSH levels can be seen in various nonthyroidal diseases. Simultaneous
measurement of TSH with free T4 is useful in evaluating the differential diagnosis.
5.It is important to confirm any TSH abnormality in a fresh specimen drawn after ~ 3 weeks before assigning a diagnosis as the
cause of an isolated TSH abnormality.

For pregnant Bio Ref Range for TSH in uIU/ml (As per American Thyroid
females Association)
First trimester 0.1 - 2.5
Second trimester 0.2 – 3.0
Third trimester 0.3 – 3.0

Page 7 of 10

SIN No:IM06081397
This test is performed by Apollo Diagnostics Lab in collaboration with Avishkar Diagnostics
Patient Name : Mr.CHANDAN TANTI Collected : 31/Aug/2023 10:13AM
Age/Gender : 23 Y 0 M 0 D /M Received : 31/Aug/2023 05:39PM
UHID/MR No : DSNG.0000003266 Reported : 31/Aug/2023 06:45PM
Visit ID : DSNGOPV4501 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC SAGARBHANGA
IP/OP NO : Patient location : RANIGANJ,RANIGANJ

DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Unit Bio. Ref. Range Method

COMPLETE URINE EXAMINATION (CUE) , URINE

PHYSICAL EXAMINATION
COLOUR PALE STRAW PALE YELLOW Visual
TRANSPARENCY HAZY CLEAR Visual
pH 6.0 5-7.5 Bromothymol Blue
SP. GRAVITY 1.020 1.002-1.030 Dipstick
BIOCHEMICAL EXAMINATION
URINE PROTEIN NEGATIVE NEGATIVE PROTEIN ERROR OF
INDICATOR
GLUCOSE NEGATIVE NEGATIVE GOD-POD
URINE BILIRUBIN NEGATIVE NEGATIVE AZO COUPLING
URINE KETONES (RANDOM) NEGATIVE NEGATIVE NITROPRUSSIDE
UROBILINOGEN NORMAL NORMAL EHRLICH
BLOOD NEGATIVE NEGATIVE Dipstick
NITRITE NEGATIVE NEGATIVE Dipstick
LEUCOCYTE ESTERASE NEGATIVE NEGATIVE PYRROLE
HYDROLYSIS
CENTRIFUGED SEDIMENT WET MOUNT AND MICROSCOPY
PUS CELLS 3-4 /hpf 0-5 Microscopy
EPITHELIAL CELLS 0-2 /hpf <10 MICROSCOPY
RBC 0-2 /hpf 0-2 MICROSCOPY
CASTS NIL 0-2 Hyaline Cast MICROSCOPY
CRYSTALS NIL ABSENT MICROSCOPY
OTHERS NIL MICROSCOPY

Page 8 of 10

SIN No:C02230693
This test is performed by Apollo Diagnostics Lab in collaboration with Avishkar Diagnostics
Patient Name : Mr.CHANDAN TANTI Collected : 31/Aug/2023 10:13AM
Age/Gender : 23 Y 0 M 0 D /M Received : 31/Aug/2023 05:39PM
UHID/MR No : DSNG.0000003266 Reported : 31/Aug/2023 06:45PM
Visit ID : DSNGOPV4501 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC SAGARBHANGA
IP/OP NO : Patient location : RANIGANJ,RANIGANJ

DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Unit Bio. Ref. Range Method

STOOL ROUTINE EXAMINATION , STOOL

PHYSICAL EXAMINATION
COLOUR BROWN Macroscopy
CONSISTENCY SEMISOLID Macroscopy
MUCUS PRESENT ABSENT Macroscopy
CHEMICAL EXAMINATION
OCCULT BLOOD NEGATIVE NEGATIVE Guaiac Method
pH 7.5 5-7.5 Double Indicator
MICROSCOPIC EXAMINATION
PUS CELLS 2-3 /hpf 0-5 Microscopy
RED BLOOD CELLS 0-2 /hpf Nil Microscopy
OVA ABSENT ABSENT Lugols Iodine
CYSTS ABSENT ABSENT Lugols Iodine
EPITHELIAL CELLS NIL /hpf <10 MICROSCOPY
VEGETABLE CELLS PRESENT ABSENT Microscopy
MUSCLE FIBRES ABSENT ABSENT Microscopy
STARCH GRANULES ABSENT ABSENT Microscopy
FAT GLOBULES ABSENT ABSENT Microscopy
OTHERS BACTERIA++ MICROSCOPY

Page 9 of 10

SIN No:C02230694
This test is performed by Apollo Diagnostics Lab in collaboration with Avishkar Diagnostics
Patient Name : Mr.CHANDAN TANTI Collected : 31/Aug/2023 10:13AM
Age/Gender : 23 Y 0 M 0 D /M Received : 31/Aug/2023 05:33PM
UHID/MR No : DSNG.0000003266 Reported : 31/Aug/2023 07:50PM
Visit ID : DSNGOPV4501 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC SAGARBHANGA
IP/OP NO : Patient location : RANIGANJ,RANIGANJ

DEPARTMENT OF SEROLOGY
Test Name Result Unit Bio. Ref. Range Method

(VDRL) RPR QUALITATIVE , SERUM NON REACTIVE NON-REACTIVE IMMUNOCHROMATOGRAPHY

Comment:
This is a screening test and reactive results must be correlated with supportive clinical, historical and epidemiological evidence to
arrive at a final diagnosis. False positives may be seen in a variety of acute and chronic conditions. It is advisable to confirm
diagnosis by TPHA / FTA-Abs test.

HBsAg , SERUM 0.01 RFV <0.13 ELFA

Comment:
RESULT IN RFV INTERPRETATION
< 0.13 NEGATIVE
≥ 0.13 POSITIVE

This assay detects the first serological marker of Hepatitis B as early as 4-16 weeks after exposure. It persists during acute illness
and disappears 12-20 weeks after onset of symptoms. The titers rise rapidly during the period of viral replication and is frequently
associated with infectivity. Persistence of HBsAg for more than 6 months indicates development of carrier state or chronic liver
disease.
It is recommended that a positive result of HBsAg must be be confirmed using a different enzyme immunoassay kit or by using a
confirmatory assay based on neutralisation with human anti hepatitis B surface antibody.
Based upon clinical history it may become necessary to test for presence of other markers of hepatitis B virus infection.

*** End Of Report ***

Page 10 of 10

SIN No:SE01782414
This test is performed by Apollo Diagnostics Lab in collaboration with Avishkar Diagnostics
 R es u lt R ep o rt

PatientID:
Record Date: 2023-08-31 21.35.28
Barcode: BI15853713
Sam pleNo: 08310018
CALIB : Y = 1.1716X + 0.0499

NAME % TIME AREA

A1A 0.3 0.25 12.56

A1B 0.9 0.33 33.54

F 0.4 0.42 16.60

LA1C+ 1.3 0.55 48.09

SA1C 5.0 0.69 158.65

A0 93.2 1.02 3475.47

TOTAL AREA 3744.91
Hb A 1C 5.0 %
HbA1 6.3 % HbF 0.4 %
[%]
15.0

10.0

5.0

0.0
0.00 1.00 2.00
[Min]

2023-08-31 21.36 root Page: 1 / 1